Business
Roctavian (BioMarin Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key market opportunities include advancements in gene delivery, growing demand for durable hemophilia treatments, increased healthcare investments, and expanding personalized medicine frameworks. The rise in hemophilia prevalence and the shift towards one-time gene therapies also provide significant growth prospects.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Roctavian Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's
About this update from Biomarin Pharmaceutical Inc.
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Key market opportunities include advancements in gene delivery, growing demand for durable hemophilia treatments, increased healthcare investments, and expanding personalized medicine frameworks. The rise in hemophilia prevalence and the shift towards one-time gene therapies also provide significant growth prospects.","length":318,"tagName":"p"},{"type":"text","content":"Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Roctavian Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.","length":211,"tagName":"p"},{"type":"text","content":"The Roctavian market is experiencing significant growth, both historically and in future forecasts. Historically, advances in gene delivery technologies, improved clinical understanding of hemophilia genetics, and early regulatory approvals have driven market growth. Additionally, the expansion of specialty treatment centers and increased patient enrollment in gene therapy trials have contributed to this growth.","length":415,"tagName":"p"},{"type":"text","content":"Looking forward, the market is expected to flourish due to rising investments in curative genetic therapies and a growing demand for durable hemophilia treatments. The expansion of personalized medicine frameworks, along with the adoption of value-based reimbursement models and continual innovations in vector engineering, are further supporting the market's expansion. Key trends for the forecast period include the rise of one-time gene therapy treatments, a focus on long-term disease modification, advanced viral vector technologies, and increased integration of precision genetic diagnostics with enhanced post-therapy outcome monitoring.","length":648,"tagName":"p"},{"type":"text","content":"The increasing prevalence of hemophilia i...